

Summary of risk management plan for Gabrion 600 mg and 800 mg film-coated tablets (gabapentin) Orion Corporation

Date: 23.08.2018, Version 2

This is a summary of the risk management plan (RMP) for Gabrion. The RMP details important risks of Gabrion, how these risks can be minimized, and how more information will be obtained about Gabrion's risks and uncertainties (missing information).

Gabrion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Gabrion should be used.

Important new concerns or changes to the current ones will be included in updates of Gabrion's RMP

I. The medicine and what it is used for

Gabrion is authorised for treatment of epilepsy and treatment of peripheral neuropathic pain (see SmPC for the full indication). It contains gabapentin as the active substance and it is given by mouth.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Gabrion, together with measures to minimise such risks and the proposed studies for learning more about Gabrion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

This product has no safety concerns requiring additional pharmacovigilance actions or additional risk minimisation activities.

Safety concerns are adequately addressed in the product information.

The safety information in the product information is aligned to the reference medicinal product.

II.B Summary of important risks

The safety information in the product information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

There are no studies required for Gabrion.